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Abstract
Background: The aim of the study was to evaluate the value of high-sensitivity cardiac tro-
ponin (hs-cTn) for identifying high-risk patients.
Methods and results: One hundred and eighty-seven patients admitted with acute heart fail-
ure (HF) (without myocardial infarction) were consecutively included; hs-cTn was measured 
at admission; the relation between elevated hs-cTn and the clinical outcome during hospitaliza-
tion and at 90 days was analyzed; 93% (n = 174) had hs-cTn above the maximal normal value  
(14 ng/L); median hs-cTn was 42 ng/L (IQR 24–81). Patients with ejection fraction (EF) ≤ 45% 
had higher hs-cTn values (p = 0.0004). Patients with low cardiac output syndrome (LCOS) 
or shock had higher troponin levels compared with those with less severe clinical presentations 
(p = 0.004). Patients who required inotropic presented higher troponin values (p = 0.002),  
troponin values were also higher in those requiring complex therapies (intra-aortic balloon 
pump, mechanical ventilation or hemodialysis, p = 0.002). At 90-day follow-up, 28 (15.5%) 
patients died and 27 rehospitalizations occurred (55 events). The risk of events was greater in 
patients with hs-cTn > 42 ng/L (0.021), low blood pressure at admission (p = 0.002), LCOS 
or shock (p < 0.0001), EF ≤ 45% (p = 0.005) and inotropic use (p < 0.0001). In multivariate 
analysis, only inotropic agents requirements was associated independently with a high risk of 
death or rehospitalizations at 90 days (p = 0.007).
Conclusions: Elevation of hs-cTn is a finding almost constant in patients with decompen-
sated HF. In subjects with higher troponin levels ventricular dysfunction is frequent. The use 
of hs-cTn for risk stratification at admission helps to identify populations with poor outcome 
during hospitalization and increased risk of death or rehospitalizations during follow-up who 
will require rapid implementation of aggressive treatment. (Cardiol J 2016; 23, 1: 78–83)
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Introduction 
The diagnostic role of high-sensitivity cardiac 
troponin (hs-cTn) in acute coronary syndromes 
(ACS) has been recently validated, and the useful-
ness of this biomarker has also been evaluated in 
heart failure (HF) populations [1, 2].
The initial evaluation of patients with acute HF 
should include the determination of the severity 
of the disease to indicate an early and appropriate 
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treatment, and the type of complexity of the hospi-
talization area. The value of hs-cTn for identifying 
high-risk patients has not been studied in depth 
and thus remains uncertain.
The goals of this study were: 1) to determine 
the prevalence of hs-cTn in patients with decom-
pensated HF; 2) to study the association between 
high troponin levels and the clinical outcome during 
hospitalization, and 3) to evaluate the association 
between troponin levels and the clinical outcome 
at 90 days.
Methods
Study population
One hundred and eighty-seven patients admit-
ted between January 2013 and March 2014 to the 
intensive care unit of the Instituto Cardiovascular 
de Buenos Aires with decompensated HF were 
consecutively included.
Patients < 18 years old, those with ACS (de-
fined by elevated cardiac enzymes associated with 
chest pain and/or electrocardiographic changes) or 
resuscitated from cardiac arrest were excluded.
The diagnosis of HF was based on the anam-
nesis, physical examination and the results of the 
complementary tests.
Ischemic etiology was defined as the presence 
of previous myocardial infarction (Q waves in two 
contiguous electrocardiographic leads), history of 
reperfusion (percutaneous coronary intervention 
or revascularization surgery) or coronary artery 
disease documented by coronary angiography (left 
main coronary artery stenosis > 50% or stenosis 
of other coronary vessel > 70%).
A categorical variable was defined from the 
variable ejection fraction (EF) and patients were 
divided in two groups, based on a cutoff point of 45%: 
one with EF > 45% and the other with EF ≤ 45%.
A categorical variable was defined from the 
variable hs-cTn, and patients were divided in two 
groups based on a cutoff point of 42 ng/L (median 
value observed): one with hs-cTn > 42 ng/L and 
the other with hs-cTn ≤ 42 ng/L.
“Complex therapy” was defined of the necessity 
of any of the following treatments: intra-aortic bal-
loon pump, mechanical ventilation or hemodialysis.
The patients were followed-up at 90 days 
after discharge by telephone calls or by revising 
the medical record. An event was defined as the 
occurrence of death and/or readmission due to 
decompensated HF within 90 days.
The protocol was conducted following the rec-
ommendations of the Declaration of Helsinki and 
all the patients signed an informed consent form. 
The protocol was approved by the Committee on 
Ethics of our institution.
Troponin measurement
Troponin was measured after the admission 
at the emergency room, using a commercially 
available kit (ECLIA Elecsys 2010 analyzer, Roche 
Diagnostics, Germany). A value < 14 ng/L was 
considered normal. Troponin values above the 
median of the sample were considered elevated.
Statistical analysis
Categorical variables were expressed as fre-
quencies and percentages and continuous variables 
as means and standard deviation or medians with 
their corresponding 25–75% interquartile range 
(IQR), as applicable.
The differences between the categorical vari-
ables were estimated using the c2 test. The dif-
ferences between the medians defined by the 
categorical variables were compared using the 
Wilcoxon test.
As the variable troponin was asymmetric and 
skewed to the right, with a wide range of values, 
logarithmic transformation was used to improve the 
visualization of the data, obtaining values between 
1 and 6, approximately. We also evaluated if logarith-
mic transformation (used in the references) could 
normalize the data. The odds ratio and hazard ratio 
(HR) were calculated with their corresponding 95% 
confidence interval (CI). The Rothman method was 
used to estimate the HR of the CI.
Logistic regression analysis was performed to 
determine the variables associated or not with the 
event at 90 days. The association between hs-cTn 
level and the probability of events at 90 days, and 
the association between each variable of interest 
with such probability were analyzed using univari-
ate and multivariate Cox regression analyses. The 
validity of the assumption of Cox proportional haz-
ards was analyzed with a global test and for each 
variable using adequate tests. The Cox-Mantel test 
was used to compare the survival curves between 
the different groups. Survival was estimated using 
the Kaplan-Meier method. Statistical analysis was 
performed using the software packages R v. 3.0.1., 
SPSS v. 20, InfoStat v. 2014py, STATA v. 12IC.
Results
One hundred and eighty-seven patients admit-
ted between January 2013 and March 2014 with 
decompensated HF were consecutively included.
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The principal characteristics of the population 
are described in Table 1. Ischemic etiology was pre-
sent in about 50% of patients with HF, and 53.8% 
(n = 100, 1 missing datum) had an EF < 45%. In 
93% of patients (n = 174), hs-cTn was above the 
maximal normal value (14 ng/L); median troponin 
level at admission was 42 ng/L (IQR 24–81). The 
most common clinical presentation was systemic 
congestion (n = 144, 77%). Patients were hospi-
talized for a median of 5 days (95% CI 4–8) and 
12 patients (6.4%) died during hospitalization.
The history of chronic kidney failure was as-
sociated with elevated troponin values (51 ng/L, 
IQR 33–72 vs. 31 ng/L, IQR 22–57, respectively, 
p = 0.002). In the same way, patients with ischemic 
etiology had significantly higher troponin values 
compared with those without ischemic etiol-
ogy (49 ng/L, IQR 25–75: 26–82 vs. 34 U/L, IQR 
25–75: 22–62, respectively, p = 0.021) (Fig. 1). 
There were no significant differences in sex, age 
or blood pressure at admission. Patients with left 
ventricular (LV) EF ≤ 45% had higher troponin 
values (43 ng/L, IQR 25–67 vs. 25 ng/L, IQR 16–30, 
p = 0.0004) (Fig. 2).
Patients with low cardiac output syndrome or 
cardiogenic shock at admission had higher troponin 
levels compared with those with less severe clini-
Table 1. Characteristics of the population.
Characteristic Value (n = 187)
Age 78 (SD ± 11)
Male sex 108 (57.8%)
Ischemic etiology 87 (46.5%)
Cardiovascular risk factors:
Current smoker 9 (4.8%)
Hypertension 153 (81.8%)
Diabetes 46 (24.6%)
Dyslipidemia 110 (58.88%)
Chronic kidney failure 73 (39%)
Left ventricular ejection fraction 40% (IQR 29–60)
Previous medication:
Beta-blockers 119 (64%)
ACEI/ARB 95 (51.1%)
Aldosterone antagonists 59 (31.7%)
Blood pressure at admission  
[mm Hg]
125 (IQR 110–141)
Low cardiac output syndrome/ 
/shock at admission
16 (8.6%)
HVRAF at admission 31 (16.6%)
Laboratory tests:
Glycemia [mg/dL] 144 (IQR 117–192)
Hemoglobin [mg/dL] 10.6 (IQR 9-12)
Creatinine [mg/dL] 1.8 (IQR 1.4–2.5)
Troponin [ng/L] 42 (IQR 24–81)
Hospital stay [days] 5 (IQR 4–8)
Use of inotropic agents 19 (10.2%)
Use of intra-aortic balloon pump 4 (2.1%)
Use of mechanical ventilation 5 (2.7%)
Use of hemodialysis 9 (4.8%)
ACEI/ARB — angiotensin-converting enzyme inhibitors/angiotensin 
II receptor blockers; HVRAF — high ventricle rate atrial fibrillation; 
IQR — interquartile range; SD — standard deviation
Figure 1. Statistically significant differences of troponin 
values according to etiology (p = 0.039).
Figure 2. Distribution of troponin values according 
to left ventricular ejection fraction (LVEF) > or ≤ 45% 
(p = 0.0004).
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cal presentations (73 ng/L, IQR 53–113 vs. 39 ng/L, 
IQR 24–58, p = 0.004).
During hospitalization, those who required 
inotropic agents presented  higher troponin values 
at admission (76 ng/L, IQR 50–107 vs. 39 ng/L, IQR 
23–58, p = 0.002), and troponin values at admis-
sion were also higher in those requiring complex 
therapies as intra-aortic balloon pump, mechanical 
ventilation or hemodialysis (86 ng/L, IQR 57–131 
vs. 40 ng/L, IQR 23–58, p = 0.002). Median hospi-
talization stay was longer in patients with elevated 
troponin values (> 42 ng/L) (5 days, IQR 3–8 vs. 
6 days, IQR 4–9, p = 0.03).
Follow-up at 90 days
Six patients were lost during follow-up, 
28 (15.5%) patients died and 27 rehospitalizations oc-
curred (55 events). Median survival was 81 days for 
patients with hs-cTn < 42 ng/L (95% CI 77–85.9) 
and 73.6 days for patients with hs-Tn > 42 ng/L 
(95% CI 67.8–79.5); this difference had statistical 
significant (Cox-Mantel test p = 0.018) (Fig. 3). 
The probability of not having an event at 90 days 
was estimated in 0.775 (95% CI 0.689–0.862) for 
patients with hs-cTn < 42 ng/L and 0.615 (95% CI 
0.515–0.715) for those with higher values.
In patients with hs-cTn > 42 ng/L, the risk of 
death or rehospitalization at 90 days was greater 
than in patients with low blood pressure at admis-
sion, low cardiac output syndrome or cardiogenic 
shock, LV EF ≤ 45% and use of inotropic agents 
(Table 2). Multivariate analysis showed that the 
use of inotropic agents was the unique variable that 
predicted increased risk of death or rehospitaliza-
tions at 90 days (Table 3).
Discussion
Cardiac troponin constitutes a well established 
diagnostic tool in ACS [1]. Troponins are released 
into the circulation as an expression of myocardial 
necrosis and have been widely investigated in HF 
populations [3, 4]. As in other series, elevated hs-
cTn levels were almost constant in the population 
studied [5, 6]. The progressive loss of myocytes in 
HF is greater during exacerbations due to increased 
capillary pulmonary pressure, lower coronary per-
fusion pressure, greater release of catecholamines, 
abnormal calcium metabolism, greater oxidative 
stress, and inflammation, etc. This produces higher 
levels of circulating troponin as an expression of 
myocardial damage [7, 8]. Up to the present time, 
the published studies have evaluated conventional 
troponin, and most of them demonstrated elevated 
troponin levels independently of the etiology of 
HF. We believe that our study is the first one to 
demonstrate that subjects with coronary artery 
Table 2. Variables associated with greater risk of rehospitalization or death at 90 days.
Variable P Hazard ratio (HR) 95% confidence interval for HR
Lower limit Upper limit
Median troponin 42 ng/L 0.021 1.911 1.1 3.3
Inotropic agent < 10–6 5.45 2.98 9.96
Interquartile range 0.155 1.468 0.87 2.5
Left ventricular ejection fraction ≤ 45% 0.005 2.37 1.31 4.3
Systolic blood pressure at admission 0.002 0.983 0.97 0.99
Age 0.37 0.990 0.97 1.01
Low cardiac output/shock 0.0001 4.5 2.3 8.8
Figure 3. Survival and risk of hospitalizations according 
to troponin level (categorical variable 42 ng/L). 
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disease have greater hs-cTn levels than those with 
other etiologies. With the exception of the study 
published by Peacock et al. [9], the other authors 
have not been able to demonstrate a statistically 
significant difference according to the etiology [10, 
11]. A possible explanation is that the patients with 
severe coronary stenoses may be more liable to 
the stress produced by an acute episode and, thus, 
have higher troponin levels. In this way, it may be 
interesting to determine the potential usefulness 
of the biomarker to identify patients with unknown 
etiology of HF.
Elevation of hs-cTn was associated with the 
most severe clinical profile; these patients were 
much more likely to be admitted with low cardiac 
output syndrome or cardiogenic shock or to re-
quire inotropic agents and complex therapies as 
mechanical ventilation, intra-aortic balloon pump 
or hemodialysis. Patients with higher troponin 
levels were those with ventricular dysfunction 
and required longer hospital stay. Up to now, the 
usefulness of high sensitivity cardiac troponin to 
identify patients with the most severe clinical 
profile, worse outcome during hospitalization or LV 
dysfunction has not been evaluated yet. Horwich 
et al. [10] demonstrated that in patients with ven-
tricular dysfunction referred for heart transplan-
tation, elevated cardiac troponin I was associated 
with impaired hemodynamics: higher pulmonary 
capillary wedge pressure, lower cardiac index and 
progressive LV dysfunction. The findings reported 
by Peacock et al. [9] in the ADHERE study which 
evaluated the role of standard troponin were very 
similar to those of our study: patients with higher 
troponin levels at admission presented lower blood 
pressure, had ventricular dysfunction, used more 
resources (intra-aortic balloon pump and mechani-
cal ventilation) and hospital stay was longer. These 
findings suggest that abnormally high troponin lev-
els at admission can be a useful parameter to iden-
tify patients with LV dysfunction, worse outcomes 
and greater use of resources during hospitalization. 
These patients could be admitted to critical care 
areas in order to implement the necessary treat-
ment. On the contrary, patients with lower levels 
at admission could be considered of low risk and 
thus admitted to intermediate care units.
During follow-up, high troponin levels, low 
blood pressure at admission, low cardiac output 
syndrome or cardiogenic shock, LV dysfunction, 
use of inotropic agents and complex therapies 
were associated with greater risk of mortality or 
rehospitalizations. All these variables have been 
associated with worse outcome in previous pub-
lications. The novel information provided by this 
study is the integration of predictors of adverse 
outcomes with troponin levels. As expected, the 
use of inotropic agents was a stronger predictor of 
events during follow-up compared with troponin 
levels. This finding may be explained because the 
inotropic requirements indicate a very high risk 
population where troponin elevation is not only an 
expression of myocardium damage due to the back-
ground disease but also because the inotropic drugs 
cause cellular necrosis with even more troponin 
increscent. Interestingly, in those subjects with 
less severe clinical presentations, high troponin 
levels at admission are useful in identifying the 
populations with higher risk of rehospitalizations or 
death which should undergo strict follow-up after 
discharge. High hs-cTn levels also help to identify 
patients requiring hospitalization in critical care 
areas and invasive therapies.
The absence of serial troponin determinations 
during hospitalization is one of the limitations of 
this study, as we could not evaluate the biological 
behavior of the biomarker and the modifications 
produced by the treatments. As we did not use 
other biomarkers already studied in HF, as conven-
tional troponin or natriuretic peptides, we could not 
make comparisons between them to identify the 
best marker for patients’ stratification.
Table 3. Multivariate analysis to predict risk of hospitalization or death at 90 days.
Variable P Hazard ratio (HR) 95% confidence interval for HR
Lower limit Upper limit
Systolic blood pressure at admission 0.073 0.99 0.979 1.001
Troponin > 42 ng/L 0.077 1.678 0.948 2.977
Left ventricular ejection fraction ≤ 45% 0.136 1.628 0.858 3.088
Inotropic agents 0.008 2.926 1.318 6.498
Low cardiac output/shock 0.794 1.033 0.808 1.321
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Conclusions
Elevation of hs-cTn is a finding almost con-
stant in patients with decompensated HF. In sub-
jects with higher troponin levels, coronary artery 
disease and LV dysfunction are very frequent. The 
use of hs-cTn for risk stratification at admission 
helps to identify populations with poor outcome 
during hospitalization and higher risk of death or 
rehospitalizations during follow-up who will require 
rapid implementation of an aggressive treatment.
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